Product Code: 5091
The Global Plasma Fractionation Market was valued at USD 25.78 Billion in 2024 and is projected to reach USD 36.82 Billion by 2030, growing at a CAGR of 6.32%. This growth is driven by the increasing reliance on plasma-derived therapies to manage chronic and rare conditions, including hemophilia, primary immunodeficiency disorders, and neurological diseases like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. The expanding elderly population and a higher prevalence of immune-related and bleeding disorders are contributing to the steady demand for plasma-based products such as immunoglobulins, albumin, and clotting factors.
Market Overview |
Forecast Period | 2026-2030 |
Market Size 2024 | USD 25.78 Billion |
Market Size 2030 | USD 36.82 Billion |
CAGR 2025-2030 | 6.32% |
Fastest Growing Segment | Albumin |
Largest Market | North America |
The continuous development of plasma collection infrastructure, especially across emerging economies, is further supporting market expansion. However, challenges such as high production costs, complex regulations, and prolonged manufacturing timelines hinder scalability. Additionally, competition from recombinant and biologic alternatives presents a threat to traditional plasma-based therapies.
Key Market Drivers
Growth in Healthcare Industry
The consistent expansion of the global healthcare industry is a fundamental driver of the plasma fractionation market. Generating more than USD 4 trillion annually, the industry sees strong contributions from pharmaceuticals and biotechnology at nearly USD 850 billion, and from diagnostics and medical technology at over USD 400 billion. These investments, along with improved infrastructure and wider access to services, are supporting the increasing use of plasma-derived treatments for conditions like immunodeficiencies, hemophilia, liver disease, and trauma-related bleeding.
By 2026, hospitals worldwide are projected to number 215,977, with growth mainly concentrated in the Far East & China and the Middle East & Africa. The expansion of hospitals and specialty clinics-especially in developing regions-is enhancing plasma collection and processing capabilities. This development is enabling a more stable global supply of fractionated products, while the rise in outpatient and personalized care models is also accelerating the adoption of these therapies.
Key Market Challenges
Limited Plasma Supply & Donation Infrastructure
A critical challenge in the plasma fractionation market is the limited availability of plasma due to underdeveloped donation systems. Plasma serves as the raw material for essential therapies such as immunoglobulins and clotting factors, yet its supply remains constrained by low donor participation and inconsistent infrastructure-particularly in lower-income countries.
In many regions, plasma collection systems are sparse or nonexistent, leading to an imbalance between growing therapeutic demand and available plasma volumes. Plasmapheresis procedures require specialized equipment, skilled staff, and time, which further limits capacity and scalability, especially in resource-limited settings.
Key Market Trends
Increasing Use of Plasma Fractionation in Autoimmune and Neurological Disorders
With over 57 million liters of plasma used annually to produce critical treatments, demand for plasma-derived therapies continues to climb-especially in managing autoimmune and neurological disorders. Conditions such as CIDP, Guillain-Barre syndrome, multiple sclerosis, and myasthenia gravis are increasingly treated with fractionated products, particularly intravenous immunoglobulin (IVIG), due to its immunomodulatory benefits.
IVIG has become a standard therapy for many of these conditions, backed by its inclusion in treatment guidelines and proven efficacy. Moreover, its use is expanding beyond conventional applications to address refractory cases and relapse prevention, reinforcing its growing role in neurology and chronic care management.
Key Market Players
- Grifols S.A.
- Octapharma AG
- Intas Pharmaceuticals Ltd
- LFB S.A.
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Biotest AG
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Bharat Serums and Vaccines Limited
Report Scope
In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Plasma Fractionation Market, By Product:
- Albumin
- Immunoglobulins
- Coagulation Factors
- Protease Inhibitors
- Others
Plasma Fractionation Market, By Application:
- Neurology
- Hematology
- Oncology
- Immunology
- Others
Plasma Fractionation Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.
Available Customizations
Global Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Plasma Fractionation Market
5. Global Plasma Fractionation Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
- 5.2.2. By Application (Neurology, Hematology, Oncology, Immunology, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Market Map
6. North America Plasma Fractionation Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Plasma Fractionation Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.2. Mexico Plasma Fractionation Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.3. Canada Plasma Fractionation Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
7. Europe Plasma Fractionation Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Plasma Fractionation Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.2. Germany Plasma Fractionation Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Plasma Fractionation Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.4. Italy Plasma Fractionation Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.5. Spain Plasma Fractionation Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Application
8. Asia Pacific Plasma Fractionation Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Plasma Fractionation Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.2. India Plasma Fractionation Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.3. South Korea Plasma Fractionation Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.4. Japan Plasma Fractionation Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.5. Australia Plasma Fractionation Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
9. South America Plasma Fractionation Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Plasma Fractionation Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.2. Argentina Plasma Fractionation Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.3. Colombia Plasma Fractionation Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
10. Middle East and Africa Plasma Fractionation Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Plasma Fractionation Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Plasma Fractionation Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.3. UAE Plasma Fractionation Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Disruptions : Conflicts, Pandemics and Trade Barriers
14. Global Plasma Fractionation Market: SWOT Analysis
15. Porters Five Forces Analysis
- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Products
16. Competitive Landscape
- 16.1. Grifols S.A.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
- 16.2. Octapharma AG
- 16.3. Intas Pharmaceuticals Ltd
- 16.4. LFB S.A.
- 16.5. Takeda Pharmaceutical Company Limited
- 16.6. CSL Limited
- 16.7. Biotest AG
- 16.8. Kedrion S.p.A
- 16.9. Bio Products Laboratory Ltd.
- 16.10. Bharat Serums and Vaccines Limited
17. Strategic Recommendations
18. About Us & Disclaimer